SG10201805660WA - Methods for rna analysis - Google Patents
Methods for rna analysisInfo
- Publication number
- SG10201805660WA SG10201805660WA SG10201805660WA SG10201805660WA SG10201805660WA SG 10201805660W A SG10201805660W A SG 10201805660WA SG 10201805660W A SG10201805660W A SG 10201805660WA SG 10201805660W A SG10201805660W A SG 10201805660WA SG 10201805660W A SG10201805660W A SG 10201805660WA
- Authority
- SG
- Singapore
- Prior art keywords
- nucleic acid
- rna
- acid molecule
- catalytic nucleic
- cleavage site
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
- B01D15/163—Pressure or speed conditioning
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8827—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving nucleic acids
Abstract
METHODS FOR RNA ANALYSIS The present invention relates to the field of RNA analysis. In particular, the invention concerns the use of a catalytic nucleic acid molecule for the analysis of an RNA molecule. The invention concerns methods for analyzing the 5' terminal structures of an RNA molecule having a cleavage site for a catalytic nucleic acid molecule. In particular, the invention concerns a method for determining the presence of a cap structure in an RNA molecule having a cleavage site for a catalytic nucleic acid molecule, a method for determining the capping degree of a population of RNA molecules having a cleavage site for a catalytic nucleic acid molecule, a method for determining the orientation of the cap structure in a capped RNA molecule having a cleavage site for a catalytic nucleic acid molecule and a method for determining relative amounts of correctly capped RNA molecules and reverse-capped RNA molecules in a population of RNA molecules, wherein the population comprises correctly capped and/or reverse-capped RNA molecules that have a cleavage site for a catalytic nucleic acid molecule. Moreover, the present invention provides uses of a catalytic nucleic acid molecule. [No suitable figure]
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2013003947 | 2013-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201805660WA true SG10201805660WA (en) | 2018-08-30 |
Family
ID=49998192
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201805660WA SG10201805660WA (en) | 2013-12-30 | 2014-12-30 | Methods for rna analysis |
SG11201604198YA SG11201604198YA (en) | 2013-12-30 | 2014-12-30 | Methods for rna analysis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201604198YA SG11201604198YA (en) | 2013-12-30 | 2014-12-30 | Methods for rna analysis |
Country Status (5)
Country | Link |
---|---|
US (3) | US10648017B2 (en) |
AU (1) | AU2014375404C1 (en) |
IL (1) | IL245935A0 (en) |
SG (2) | SG10201805660WA (en) |
WO (1) | WO2015101416A1 (en) |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
BR112015018989B1 (en) | 2013-02-22 | 2023-11-14 | Curevac Ag | COMBINATION VACCINE/PD-1 PATHWAY INHIBITOR, PD-1 PATHWAY INHIBITOR AND RNA VACCINE |
WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
EP2971161B1 (en) | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Ribonucleic acid purification |
EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | Removal of dna fragments in mrna production process |
AU2014310934B2 (en) | 2013-08-21 | 2019-09-12 | CureVac SE | Respiratory syncytial virus (RSV) vaccine |
AU2014310931B2 (en) | 2013-08-21 | 2019-12-19 | CureVac SE | Rabies vaccine |
CA2915730A1 (en) | 2013-08-21 | 2015-02-26 | Karl-Josef Kallen | A combination rsv/influenza a vaccine |
MX2016002152A (en) | 2013-08-21 | 2017-01-05 | Curevac Ag | Method for increasing expression of rna-encoded proteins. |
WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
WO2015101416A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Methods for rna analysis |
US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
JP6584414B2 (en) | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | Artificial nucleic acid molecule |
CN105874072A (en) | 2013-12-30 | 2016-08-17 | 库瑞瓦格股份公司 | Artificial nucleic acid molecules |
US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
BR112016026980B1 (en) | 2014-06-10 | 2022-05-03 | Curevac Real Estate Gmbh | Method for synthesizing an RNA molecule of a given sequence |
EP3157573A4 (en) | 2014-06-19 | 2018-02-21 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
AU2015289656A1 (en) | 2014-07-16 | 2017-02-16 | Modernatx, Inc. | Circular polynucleotides |
EP4241784A3 (en) | 2014-12-12 | 2023-11-15 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
WO2016165825A1 (en) | 2015-04-13 | 2016-10-20 | Curevac Ag | Method for producing rna compositions |
EP3283125B1 (en) | 2015-04-17 | 2021-12-29 | CureVac Real Estate GmbH | Lyophilization of rna |
AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
EP3289101B1 (en) | 2015-04-30 | 2021-06-23 | CureVac AG | Immobilized poly(n)polymerase |
WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
CA2975816A1 (en) | 2015-05-15 | 2016-11-24 | Curevac Ag | Prime-boost regimens involving administration of at least one mrna construct |
SG11201708541QA (en) | 2015-05-20 | 2017-12-28 | Curevac Ag | Dry powder composition comprising long-chain rna |
EP3916091A3 (en) | 2015-05-20 | 2022-03-30 | CureVac AG | Dry powder composition comprising long-chain rna |
PL3303583T3 (en) | 2015-05-29 | 2020-10-19 | Curevac Real Estate Gmbh | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
EP4098743A1 (en) | 2015-05-29 | 2022-12-07 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
EP3317424B1 (en) * | 2015-07-01 | 2023-09-06 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
WO2017009376A1 (en) | 2015-07-13 | 2017-01-19 | Curevac Ag | Method of producing rna from circular dna and corresponding template dna |
WO2017036580A1 (en) | 2015-08-28 | 2017-03-09 | Curevac Ag | Artificial nucleic acid molecules |
PT3350157T (en) | 2015-09-17 | 2022-03-18 | Modernatx Inc | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2017049286A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
SI3362461T1 (en) | 2015-10-16 | 2022-05-31 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
WO2017066793A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
US11413346B2 (en) | 2015-11-09 | 2022-08-16 | Curevac Ag | Rotavirus vaccines |
EP3656872A1 (en) | 2015-12-09 | 2020-05-27 | Novartis AG | Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry |
US10799463B2 (en) | 2015-12-22 | 2020-10-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
US11684665B2 (en) | 2015-12-22 | 2023-06-27 | CureVac SE | Method for producing RNA molecule compositions |
EP3394280A1 (en) | 2015-12-23 | 2018-10-31 | CureVac AG | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
WO2017140345A1 (en) | 2016-02-15 | 2017-08-24 | Curevac Ag | Method for analyzing by-products of rna in vitro transcription |
SG11201806340YA (en) | 2016-02-17 | 2018-09-27 | Curevac Ag | Zika virus vaccine |
WO2017149139A1 (en) | 2016-03-03 | 2017-09-08 | Curevac Ag | Rna analysis by total hydrolysis |
EP3448427A1 (en) | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
EP3452493A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Nucleic acid molecules and uses thereof |
WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
EP3468613A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Hybrid carriers for nucleic acid cargo |
JP2019525901A (en) | 2016-06-14 | 2019-09-12 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Stabilized preparation of lipid nanoparticles |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
JP2020501545A (en) | 2016-12-08 | 2020-01-23 | キュアバック アーゲー | RNA for treatment or prevention of liver disease |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
US11464847B2 (en) | 2016-12-23 | 2022-10-11 | Curevac Ag | Lassa virus vaccine |
EP3558355A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Henipavirus vaccine |
EP3595727A1 (en) | 2017-03-15 | 2020-01-22 | ModernaTX, Inc. | Lipid nanoparticle formulation |
WO2018170306A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
BR112019015244A2 (en) | 2017-03-24 | 2020-04-14 | Curevac Ag | nucleic acids encoding proteins associated with crispr and uses thereof |
WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
EP3638678A1 (en) | 2017-06-14 | 2020-04-22 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
SG11201911430PA (en) | 2017-07-04 | 2020-01-30 | Curevac Ag | Novel nucleic acid molecules |
WO2019036638A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Methods of preparing modified rna |
EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
RU2020117848A (en) | 2017-11-08 | 2021-12-08 | Куревак Аг | PHK SEQUENCE ADAPTATION |
EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
SG11202005760PA (en) | 2017-12-21 | 2020-07-29 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
EP3852728A1 (en) | 2018-09-20 | 2021-07-28 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
SG11202106666UA (en) | 2018-12-21 | 2021-07-29 | Curevac Ag | Methods for rna analysis |
US20220040281A1 (en) | 2018-12-21 | 2022-02-10 | Curevac Ag | Rna for malaria vaccines |
SG11202108098QA (en) | 2019-01-31 | 2021-08-30 | Modernatx Inc | Vortex mixers and associated methods, systems, and apparatuses thereof |
WO2020160397A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
WO2020254535A1 (en) | 2019-06-18 | 2020-12-24 | Curevac Ag | Rotavirus mrna vaccine |
KR20220047319A (en) | 2019-08-14 | 2022-04-15 | 큐어백 아게 | RNA Combinations and Compositions with Reduced Immunostimulatory Properties |
WO2021156267A1 (en) | 2020-02-04 | 2021-08-12 | Curevac Ag | Coronavirus vaccine |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
JP2023529522A (en) | 2020-04-09 | 2023-07-11 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | Lipid nanoparticle composition |
TW202204622A (en) | 2020-04-09 | 2022-02-01 | 大陸商蘇州艾博生物科技有限公司 | Nucleic acid vaccines for coronavirus |
WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
EP3993828A1 (en) | 2020-05-29 | 2022-05-11 | CureVac AG | Nucleic acid based combination vaccines |
CN114206463A (en) | 2020-06-30 | 2022-03-18 | 苏州艾博生物科技有限公司 | Lipid compounds and lipid nanoparticle compositions |
EP4172194A1 (en) | 2020-07-31 | 2023-05-03 | CureVac SE | Nucleic acid encoded antibody mixtures |
CN112111558A (en) * | 2020-08-19 | 2020-12-22 | 翌圣生物科技(上海)有限公司 | Method for determining activity of capping enzyme of vaccinia virus |
WO2022037652A1 (en) | 2020-08-20 | 2022-02-24 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
EP4157344A2 (en) | 2020-08-31 | 2023-04-05 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
KR20230164648A (en) | 2020-12-22 | 2023-12-04 | 큐어백 에스이 | RNA vaccines against SARS-CoV-2 variants |
CA3171051A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
WO2022152109A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2022152141A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Polymer conjugated lipid compounds and lipid nanoparticle compositions |
US20240102065A1 (en) | 2021-01-27 | 2024-03-28 | CureVac SE | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
CA3212653A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
EP4312988A2 (en) | 2021-03-31 | 2024-02-07 | CureVac SE | Syringes containing pharmaceutical compositions comprising rna |
CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
CA3211623A1 (en) | 2021-05-24 | 2022-12-01 | Bo YING | Lipid compounds and lipid nanoparticle compositions |
WO2023006999A2 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Mrnas for treatment or prophylaxis of liver diseases |
WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
CA3231523A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
TW202328067A (en) | 2021-09-14 | 2023-07-16 | 美商雷納嘉德醫療管理公司 | Cyclic lipids and methods of use thereof |
EP4204391A1 (en) | 2021-10-08 | 2023-07-05 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
CN116064598B (en) | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | Nucleic acid vaccine for coronavirus |
AR127312A1 (en) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023138786A1 (en) * | 2022-01-21 | 2023-07-27 | BioNTech SE | Analysis of rna molecules using catalytic nucleic acids |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
CN114894916A (en) * | 2022-04-02 | 2022-08-12 | 翌圣生物科技(上海)股份有限公司 | Method for detecting RNA capping efficiency |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024037578A1 (en) | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
CN116875658B (en) * | 2023-09-09 | 2024-02-06 | 南京鸿明生物科技有限公司 | Deoxyribozyme and method for detecting mRNA capping rate |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ308970A (en) * | 1995-06-07 | 1999-10-28 | Commw Scient Ind Res Org | Optimized minizymes and miniribozymes and uses thereof |
US7034009B2 (en) * | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US20030069195A1 (en) * | 1996-03-01 | 2003-04-10 | Farrar Gwenyth Jane | Suppression of polymorphic alleles |
AU4739600A (en) * | 1999-05-17 | 2000-12-05 | Mcgill University | Method for subtracting cdnas by suppressing the synthesis of specifically targeted mrnas |
JP2004525602A (en) | 2000-04-13 | 2004-08-26 | メディカル ユニバーシティー オブ サウス カロライナ | Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of using them |
EP1832603B1 (en) | 2001-06-05 | 2010-02-03 | CureVac GmbH | Stabilised mRNA with increased G/C-content encoding a bacterial antigen and its use |
JP4216716B2 (en) | 2001-08-09 | 2009-01-28 | ウォーターズ・インヴェストメンツ・リミテッド | Porous organic / inorganic hybrid monolithic material for chromatographic separation and method for producing the same |
DE10162480A1 (en) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | The application of mRNA for use as a therapeutic agent against tumor diseases |
US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
DE10229872A1 (en) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immune stimulation through chemically modified RNA |
DE10335833A1 (en) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfection of blood cells with mRNA for immune stimulation and gene therapy |
US20050287539A1 (en) | 2004-06-29 | 2005-12-29 | Emmanuel Labourier | Methods and compositions for preparing capped RNA |
DE102004042546A1 (en) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Combination therapy for immune stimulation |
KR20070111448A (en) * | 2004-11-08 | 2007-11-21 | 예일 유니버시티 | Riboswitches, structure-based compound design with riboswitches, and methods and compositions for use of and with riboswitches |
DE102005023170A1 (en) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimized formulation for mRNA |
EP2049665A2 (en) | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
DE102006035618A1 (en) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | New nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria |
DE102006061015A1 (en) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Process for the purification of RNA on a preparative scale by HPLC |
DE102007001370A1 (en) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
CN104072561B (en) | 2007-06-19 | 2017-12-22 | 路易斯安那州州立大学及农业机械学院管理委员会 | The synthesis of the anti-reverse phosphorothioate analogs of mRNA cap and purposes |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
AU2009210266B2 (en) | 2008-01-31 | 2015-01-29 | CureVac SE | Nucleic acids comprising formula (NuGlXmGmGnNv)a and derivatives thereof as an immunostimulating agents/adjuvants |
PL215513B1 (en) | 2008-06-06 | 2013-12-31 | Univ Warszawski | New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
DK2449113T3 (en) | 2010-07-30 | 2016-01-11 | Curevac Ag | Complex formation of nucleic acids with the disulfide cross-linked cationic components for transfection and immunostimulation |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
AU2012236099A1 (en) * | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
WO2013059475A1 (en) | 2011-10-18 | 2013-04-25 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
AU2013242403B2 (en) | 2012-03-27 | 2018-10-18 | Curevac Ag | Artificial nucleic acid molecules |
WO2013143700A2 (en) | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
DK2831241T3 (en) | 2012-03-27 | 2017-11-06 | Curevac Ag | ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN OR PEPTIDE EXPRESSION. |
US20150306249A1 (en) | 2012-05-25 | 2015-10-29 | Curevac Gmbh | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
BR112015018989B1 (en) | 2013-02-22 | 2023-11-14 | Curevac Ag | COMBINATION VACCINE/PD-1 PATHWAY INHIBITOR, PD-1 PATHWAY INHIBITOR AND RNA VACCINE |
MX2015011944A (en) * | 2013-03-14 | 2015-12-01 | Shire Human Genetic Therapies | Quantitative assessment for cap efficiency of messenger rna. |
AU2014310931B2 (en) | 2013-08-21 | 2019-12-19 | CureVac SE | Rabies vaccine |
RU2016109938A (en) | 2013-08-21 | 2017-09-26 | Куревак Аг | COMPOSITION AND VACCINE FOR TREATMENT OF PROSTATE CANCER |
MX2016002152A (en) | 2013-08-21 | 2017-01-05 | Curevac Ag | Method for increasing expression of rna-encoded proteins. |
CN105530952A (en) | 2013-08-21 | 2016-04-27 | 库瑞瓦格股份公司 | Composition and vaccine for treating lung cancer |
AU2014310934B2 (en) | 2013-08-21 | 2019-09-12 | CureVac SE | Respiratory syncytial virus (RSV) vaccine |
CA2915730A1 (en) | 2013-08-21 | 2015-02-26 | Karl-Josef Kallen | A combination rsv/influenza a vaccine |
WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
JP6584414B2 (en) | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | Artificial nucleic acid molecule |
WO2015101416A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Methods for rna analysis |
CN105874072A (en) | 2013-12-30 | 2016-08-17 | 库瑞瓦格股份公司 | Artificial nucleic acid molecules |
WO2015135558A1 (en) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combination of vaccination and ox40 agonists |
US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
BR112016026980B1 (en) | 2014-06-10 | 2022-05-03 | Curevac Real Estate Gmbh | Method for synthesizing an RNA molecule of a given sequence |
EP4241784A3 (en) | 2014-12-12 | 2023-11-15 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
EP3233113A1 (en) | 2014-12-16 | 2017-10-25 | CureVac AG | Ebolavirus and marburgvirus vaccines |
CN107124889A (en) | 2014-12-30 | 2017-09-01 | 库瑞瓦格股份公司 | Artificial nucleic acid molecule |
AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
EP3317424B1 (en) | 2015-07-01 | 2023-09-06 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
-
2014
- 2014-12-30 WO PCT/EP2014/003482 patent/WO2015101416A1/en active Application Filing
- 2014-12-30 SG SG10201805660WA patent/SG10201805660WA/en unknown
- 2014-12-30 AU AU2014375404A patent/AU2014375404C1/en active Active
- 2014-12-30 SG SG11201604198YA patent/SG11201604198YA/en unknown
-
2016
- 2016-05-31 IL IL245935A patent/IL245935A0/en active IP Right Grant
- 2016-06-28 US US15/195,901 patent/US10648017B2/en active Active
-
2020
- 2020-03-04 US US16/809,375 patent/US20200216878A1/en not_active Abandoned
-
2022
- 2022-10-28 US US18/050,940 patent/US20230313268A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2015101416A1 (en) | 2015-07-09 |
US20230313268A1 (en) | 2023-10-05 |
AU2014375404C1 (en) | 2020-11-19 |
US10648017B2 (en) | 2020-05-12 |
SG11201604198YA (en) | 2016-07-28 |
WO2015101416A8 (en) | 2018-12-13 |
US20200216878A1 (en) | 2020-07-09 |
IL245935A0 (en) | 2016-07-31 |
US20160304938A1 (en) | 2016-10-20 |
AU2014375404B2 (en) | 2020-07-30 |
AU2014375404A1 (en) | 2016-06-16 |
AU2014375404A9 (en) | 2019-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201805660WA (en) | Methods for rna analysis | |
EP4239080A3 (en) | Method for analysis of an rna molecule | |
WO2016126871A3 (en) | Sequencing of nucleic acids via barcoding in discrete entities | |
GEP20217251B (en) | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription | |
WO2014145820A3 (en) | Multiple tagging of long dna fragments | |
WO2012103479A3 (en) | Gas sorption analysis of unconventional rock samples | |
EP3382019A4 (en) | Method for converting monocot plant genome sequence in which nucleic acid base in targeted dna sequence is specifically converted, and molecular complex used therein | |
WO2012042374A3 (en) | Method of determining number or concentration of molecules | |
MX2015011945A (en) | Quantitative assessment for cap efficiency of messenger rna. | |
GB201216076D0 (en) | Methods for obtaining a sequence | |
BR112014027166A2 (en) | antibody, nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation, treatment method, proliferation inhibiting method and detection methods. | |
NZ705742A (en) | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks | |
WO2012166742A3 (en) | Systems and methods for genetic and biological analysis | |
NZ705745A (en) | Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks | |
SG11201500371VA (en) | Methods of detecting dna, rna and protein in biological samples | |
WO2010144150A3 (en) | Real-time analytical methods and systems | |
WO2013050881A3 (en) | Direct nucleic acid analysis | |
BR112013020070A2 (en) | nucleic acid molecules encoding new herpes antigens, vaccine comprising them and methods of using them | |
AR091098A1 (en) | ANTIBODIES AND IMMUNOCATED TO Ly6E AND METHODS OF USE | |
EP2438151A4 (en) | Method and system for sample preparation | |
WO2014052433A3 (en) | Method and system for analysis of protein and other modifications on dna and rna | |
GB201205769D0 (en) | Methods for preparing samples for nucleic acid amplification | |
EP2463660A4 (en) | Nucleic acid element for use in analysis, and analytical method, analytical reagent and analytical instrument using same | |
EP2314680A4 (en) | Method for amplification of target nucleic acid sequence, method for detection of mutation by using the method, and reagents for use in the methods | |
WO2011121454A3 (en) | Direct nucleic acid analysis |